The mesopancreas and pancreatic head carcinoma: from preoperative imaging to histopathological and surgical outcome

The mesopancreas and pancreatic head carcinoma: from preoperative imaging to histopathological and surgical outcome - Mesopanc-01

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029558

Enrollment

500

Registered

2022-07-22

Start date

2023-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25.0

Interventions

Group 1: 1. Patients wo receive pancreatoduodenectomy for pancreatic head cancer (pylorus preserving or not

pancreatic tail preserving or not) and neoadjuvant treatment prior to surgery (reason for neoadjuvant treatment must be given: for example: primary resectable because of in other study enrollment, bor

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients who receive primary surgery patients with neoadjvuant treatment prior to surgery CRM Implemented in pathological institute according to LEEPP

Exclusion criteria

Exclusion criteria: Palliation, abort of operation, no CRM implemented in pathology institute, no preoperative CT (minimum bisphasic)

Design outcomes

Primary

Measure	Time frame
Incidence rate of mesopancreatic adipose tissue infiltration in a multicentric setting Statistical comparison of the mesopancreatic adipose tissue infiltration status with known oncologically relevant histopathological staging factors: is there a more aggressive tumor biology or an unfavorable tumor topography? Statistical comparison of mesopancreatic adipose tissue infiltration status with the CRM of the dorsal resection margin and with the entire CRM Prediction value of preoperative fat stranding in computed tomography with mesopancreatic adipose tissue infiltration status in primary and neoadjuvantly patients	—

Measure

Time frame

Incidence rate of mesopancreatic adipose tissue infiltration in a multicentric setting Statistical comparison of the mesopancreatic adipose tissue infiltration status with known oncologically relevant histopathological staging factors: is there a more aggressive tumor biology or an unfavorable tumor topography? Statistical comparison of mesopancreatic adipose tissue infiltration status with the CRM of the dorsal resection margin and with the entire CRM Prediction value of preoperative fat stranding in computed tomography with mesopancreatic adipose tissue infiltration status in primary and neoadjuvantly patients

—

Secondary

Measure	Time frame
Incidence rate of mesopancreatic adipose tissue in primary and borderline resectable pancreatic head carcinomas (classification of resectability using the well-known ABC scheme) Prediction value of preoperative fat stranding in computed tomography with the mesopancreatic adipose tissue infiltration status in primary and borderline resectable pancreatic head carcinoma Incidence rate of mesopancreatic adipose tissue infiltration in neoadjuvant and primary surgical patients (matched-pairs analysis: both patient groups (neoadjuvant vs. primary surgical) must have similar resectability criteria).	—

Measure

Time frame

Incidence rate of mesopancreatic adipose tissue in primary and borderline resectable pancreatic head carcinomas (classification of resectability using the well-known ABC scheme) Prediction value of preoperative fat stranding in computed tomography with the mesopancreatic adipose tissue infiltration status in primary and borderline resectable pancreatic head carcinoma Incidence rate of mesopancreatic adipose tissue infiltration in neoadjuvant and primary surgical patients (matched-pairs analysis: both patient groups (neoadjuvant vs. primary surgical) must have similar resectability criteria).

—

Countries

Germany

Contacts

Public ContactSami Alexander Safi

Abteilung für Allgemein-, Viszeral- und KinderchirurgieUniversitätsklinikum Düsseldorf

sami-alexander.safi@med.uni-duesseldorf.de016097937947

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026